These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 17621240)

  • 21. A clinician-nurse model to reduce early mortality and increase clinic retention among high-risk HIV-infected patients initiating combination antiretroviral treatment.
    Braitstein P; Siika A; Hogan J; Kosgei R; Sang E; Sidle J; Wools-Kaloustian K; Keter A; Mamlin J; Kimaiyo S
    J Int AIDS Soc; 2012 Feb; 15(1):7. PubMed ID: 22340703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.
    Matignon M; Lelièvre JD; Lahiani A; Abbassi K; Desvaux D; Diallo A; Peraldi MN; Taburet AM; Saillard J; Delaugerre C; Costagliola D; Assoumou L; Grimbert P;
    HIV Med; 2019 Mar; 20(3):202-213. PubMed ID: 30688008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era.
    Roul H; Mary-Krause M; Ghosn J; Delaugerre C; Pialoux G; Cuzin L; Launay O; Lacombe JM; Menard A; De Truchis P; Delfraissy JF; Weiss L; Costagliola D;
    AIDS; 2018 Nov; 32(17):2605-2614. PubMed ID: 30289817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.
    García F; de Lazzari E; Plana M; Castro P; Mestre G; Nomdedeu M; Fumero E; Martínez E; Mallolas J; Blanco JL; Miró JM; Pumarola T; Gallart T; Gatell JM
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):702-13. PubMed ID: 15167289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment.
    Bwire R; Nagelkerke NJ; Borgdorff MW
    Trop Med Int Health; 2006 Oct; 11(10):1567-75. PubMed ID: 17002731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiretroviral therapy improves survival among TB-HIV co-infected patients who have CD4+ T-cell count above 350cells/mm
    Mutembo S; Mutanga JN; Musokotwane K; Alisheke L; Whalen CC
    BMC Infect Dis; 2016 Oct; 16(1):572. PubMed ID: 27751168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
    Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE;
    Lancet Respir Med; 2016 Dec; 4(12):980-989. PubMed ID: 27773665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012.
    Cohen S; Smit C; van Rossum AM; Fraaij PL; Wolfs TF; Geelen SP; Schölvinck EH; Warris A; Scherpbier HJ; Pajkrt D;
    AIDS; 2013 Oct; 27(16):2567-75. PubMed ID: 23842124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy.
    Pantazis N; Papastamopoulos V; Paparizos V; Metallidis S; Adamis G; Antoniadou A; Psichogiou M; Chini M; Sambatakou H; Sipsas NV; Gogos C; Chrysos G; Panagopoulos P; Katsarou O; Gikas A; Touloumi G;
    AIDS; 2019 Aug; 33(10):1645-1655. PubMed ID: 31305332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.
    Bruyand M; Thiébaut R; Lawson-Ayayi S; Joly P; Sasco AJ; Mercié P; Pellegrin JL; Neau D; Dabis F; Morlat P; Chêne G; Bonnet F;
    Clin Infect Dis; 2009 Oct; 49(7):1109-16. PubMed ID: 19705973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of antiretroviral therapy initiation and treatment outcomes for people living with HIV in Vietnam.
    Tran DA; Shakeshaft A; Ngo AD; Mallitt KA; Wilson D; Doran C; Zhang L
    HIV Clin Trials; 2013; 14(1):21-33. PubMed ID: 23372112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
    Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
    AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009.
    Zhu H; Napravnik S; Eron JJ; Cole SR; Ma Y; Wohl DA; Dou Z; Zhang Y; Liu Z; Zhao D; Yu L; Liu X; Cohen MS; Zhang F
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):e150-7. PubMed ID: 23572014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Total lymphocyte count as a surrogate marker for CD4+ t cell count in initiating antiretroviral therapy at Kenyatta National Hospital, Nairobi.
    Gitura B; Joshi MD; Lule GN; Anzala O
    East Afr Med J; 2007 Oct; 84(10):466-72. PubMed ID: 18232267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population.
    Rodger AJ; Lodwick R; Schechter M; Deeks S; Amin J; Gilson R; Paredes R; Bakowska E; Engsig FN; Phillips A;
    AIDS; 2013 Mar; 27(6):973-979. PubMed ID: 23698063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does region of origin influence the timing and outcome of first-line antiretroviral therapy in France?
    Gatey C; Brun A; Hamet G; Diamantis S; Sellier P; Bouchaud O; Garrait V; Rozenbaum W; Molina JM; Abgrall S;
    HIV Med; 2019 Feb; 20(2):175-181. PubMed ID: 30506853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced renal function is associated with progression to AIDS but not with overall mortality in HIV-infected Kenyan adults not initially requiring combination antiretroviral therapy.
    Gupta SK; Ong'or WO; Shen C; Musick B; Goldman M; Wools-Kaloustian K
    J Int AIDS Soc; 2011 Jun; 14():31. PubMed ID: 21663693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes.
    Bohlius J; Schmidlin K; Boué F; Fätkenheuer G; May M; Caro-Murillo AM; Mocroft A; Bonnet F; Clifford G; Paparizos V; Miro JM; Obel N; Prins M; Chêne G; Egger M;
    Blood; 2011 Jun; 117(23):6100-8. PubMed ID: 21368291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.